Daniel H. Ryan
YOU?
Author Swipe
View article: Association between multiple sclerosis and the risk of stroke: A population-based retrospective cohort study
Association between multiple sclerosis and the risk of stroke: A population-based retrospective cohort study Open
Our findings suggest that MS is not associated with an increased risk of stroke.
View article: Experiences After Stroke-Who Needs An Interdisciplinary Clinic Anyway?
Experiences After Stroke-Who Needs An Interdisciplinary Clinic Anyway? Open
Background Unmet needs, including access to rehabilitation, support and information, are experienced by a high proportion of stroke survivors after discharge from acute and rehabilitation services (McKevitt et al.,2011). All stroke patient…
View article: The Effect of Ward Level Noise On Anxiety and Sleep In An Inpatient Population Aged Greater Than 65 Years Old
The Effect of Ward Level Noise On Anxiety and Sleep In An Inpatient Population Aged Greater Than 65 Years Old Open
Background The term “noise” is derived from the Latin word noxia, meaning “injury”. Excessive noise can negatively affect inpatients, particularly those aged over 65 by increasing stress, disrupting sleep, inducing delirium and prolonging …
View article: Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses Open
CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine in a synergistic 1:5 molar ratio, is approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplas…
View article: PB1733 OUTCOMES WITH CPX‐351 VERSUS 7+3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH‐RISK/SECONDARY AML: EXPLORATORY ANALYSIS OF A PHASE 3 STUDY
PB1733 OUTCOMES WITH CPX‐351 VERSUS 7+3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH‐RISK/SECONDARY AML: EXPLORATORY ANALYSIS OF A PHASE 3 STUDY Open
Background: CPX‐351 (Vyxeos ® ; daunorubicin and cytarabine powder for concentrate for solution for infusion), a dual‐drug liposomal encapsulation of cytarabine and daunorubicin at a synergistic ratio, is approved by the EMA and the US FDA…
View article: The Impact of Hematopoietic Cell Transplantation (HCT) on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML (sAML)
The Impact of Hematopoietic Cell Transplantation (HCT) on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML (sAML) Open
IntroductionCPX-351 (Vyxeos®), a dual-drug liposomal encapsulation of cytarabine (C) and daunorubicin (D) at a synergistic ratio, is approved by the FDA and EMA for adults with newly diagnosed therapy-related AML or AML with myelodysplasia…
View article: CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia Open
Purpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a s…
View article: 246A Review of Acute Hospital Activity Attributable to the Care of Parkinsonian Patients
246A Review of Acute Hospital Activity Attributable to the Care of Parkinsonian Patients Open
Background: Parkinson's disease (PD) is a common neurodegenerative condition.Its prevalence is 3% in those aged ≥65.PD patients are complex and at risk of adverse outcomes in the acute hospital.This study aimed to review inpatient activity…